APIE-Therapeutics is currently seeking potential investors for the opportunity to create value with our novel lead Apelin Receptor Agonist Drug Assets portfolio in various therapeutics areas.




Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, lung disease of unknown cause affecting approximately 140,000 patients in the United States, and an estimated 30,000 to 40,000 new cases are diagnosed each year.  In IPF, healthy lung tissue becomes replaced by scar tissue.  As lung fibrosis progresses, it becomes more difficult for the lungs to transfer oxygen into the bloodstream.


























Currently, there are only two FDA-approved drugs for the treatment of IPF that have limited efficacy and benefit to health outcomes. IPF patients are in urgent need of new drugs that can significantly improve health outcomes and extend lifespans.

APIE Therapeutics has compelling preclinical data package for lead molecule, potentially delaying the disease progression and promoting regeneration on the endothelial protective cells.  In preclinical studies, APT101 was shown to be efficacious in the in vivo model, well tolerated and a good safety profile.


Our novel mechanism of action biology, apelinergic system signaling path via apelin/APJ biased agonists, have a best-in class therapy potential and opportunity before us.

Contact us to get more information about the company and the compelling nonclinical studies results that supports moving the program into human clinical trials.

Contact us 


© 2020 by Apie Therapeutics. 

  • LinkedIn